Catalyst Wire Dossier Catalyst Wire Dossier

CT-P13 Subcutaneous

infliximab biosimilar · Celltrion
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CT-P13 Subcutaneous, covering 2024-07-31 to 2024-07-31. Get the full timeline:

Most recent: Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC [Phase 3]

See pricing